Four Decades for Justice
Cravath’s global private equity practice advises private equity firms and their portfolio companies on all aspects of private equity investing. Our private equity clients encompass traditional leveraged buyout funds, real estate, credit and hedge funds, as well as new and non‑traditional participants in the private equity space, including pension plans, family offices, insurance companies and sovereign wealth funds. We also advise on transactions involving special purpose acquisition companies (SPACs) and private investments in public equity (PIPEs).
Cravath’s culture of training and developing our lawyers across our core corporate practice areas produces uniquely skilled practitioners who approach private equity transactions holistically and with a depth of knowledge across all aspects of private equity investing. We combine the knowledge and experience of our mergers and acquisitions partners, together with the exceptional expertise of our finance and investment management and funds partners, to provide a significant advantage to our private equity clients, whose transactions often traverse several of these areas.
Our renowned mergers and acquisitions practice advises on a broad array of U.S., cross‑border and international transactions, ranging from strategic and minority equity investments to large precedent‑setting combinations. Our mergers and acquisitions representations often involve private equity firms, independently or as part of a consortium, which enables us to provide unique insight into the perspective of a corporate target.
Our market‑leading finance practice devises efficient and business‑oriented financing structures to meet clients’ most important capital‑raising needs. While not every matter requires complex, multicurrency, multijurisdictional financings, our private equity clients benefit from our lawyers’ deep expertise with the latest market trends and innovative financing techniques.
Cravath has also been at the forefront of legal innovation in the private equity sphere. The Firm successfully pioneered the process of creating publicly listed funds for the established U.S. private equity community. Clients further benefit from the Firm’s unparalleled expertise in antitrust, intellectual property, tax and regulatory enforcement and compliance matters.
Cravath’s culture of training and developing our lawyers across our core corporate practice areas produces uniquely skilled practitioners who approach private equity transactions holistically and with a depth of knowledge across all aspects of private equity investing. We combine the knowledge and experience of our mergers and acquisitions partners, together with the exceptional expertise of our finance and investment management and funds partners, to provide a significant advantage to our private equity clients, whose transactions often traverse several of these areas.
Our renowned mergers and acquisitions practice advises on a broad array of U.S., cross‑border and international transactions, ranging from strategic and minority equity investments to large precedent‑setting combinations. Our mergers and acquisitions representations often involve private equity firms, independently or as part of a consortium, which enables us to provide unique insight into the perspective of a corporate target.
Our market‑leading finance practice devises efficient and business‑oriented financing structures to meet clients’ most important capital‑raising needs. While not every matter requires complex, multicurrency, multijurisdictional financings, our private equity clients benefit from our lawyers’ deep expertise with the latest market trends and innovative financing techniques.
Cravath has also been at the forefront of legal innovation in the private equity sphere. The Firm successfully pioneered the process of creating publicly listed funds for the established U.S. private equity community. Clients further benefit from the Firm’s unparalleled expertise in antitrust, intellectual property, tax and regulatory enforcement and compliance matters.
Deals & Cases
September 19, 2023
On September 19, 2023, affiliates of private investment firm Lindsay Goldberg, in partnership with the company’s management, announced the completion of an investment in The Kleinfelder Group, a leading engineering, design, construction management, construction materials inspection and testing, and environmental professional services firm. Cravath is representing Lindsay Goldberg in connection with the transaction.
Deals & Cases
September 18, 2023
On September 18, 2023, OMERS Private Equity announced the signing of a definitive agreement to acquire a majority stake in Knight Commercial, a leading provider of commercial restoration services. Cravath is representing OMERS Private Equity in connection with the transaction.
Deals & Cases
September 13, 2023
On September 12, 2023, J.D. Power, a global leader in data analytics, announced a definitive agreement to acquire Autovista Group, a leading pan‑European and Australian automotive data, analytics and industry insights provider. Cravath is representing European alternative asset management firm Hayfin Capital Management, which currently owns Autovista Group, as U.S. counsel in connection with the transaction.
Deals & Cases
August 30, 2023
Cravath represented the lead arrangers in connection with senior facilities to finance the pending acquisition of Palex Medical by funds advised by the private equity firms Apax Partners LLP and Fremman Capital. Palex Medical is a leading provider of high value‑added medical technology equipment and solutions in Southern Europe.
Deals & Cases
August 15, 2023
On August 14, 2023, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, managed by DRI Capital Inc., announced that it has purchased a second royalty interest in the worldwide net sales of ORSERDU®, the first approved targeted therapy used in the treatment of postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression despite prior endocrine therapy. DRI Healthcare entered into a purchase agreement with Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. for an upfront purchase price of $130 million. In addition to running royalties, DRI Healthcare is also entitled to receive milestone payments of up to $40 million on the achievement of sales performance thresholds. Cravath represented DRI Capital Inc. in connection with the transaction.
Firm News
August 14, 2023
Between July 28 and August 11, 2023, Cravath advised on nine announced deals, including seven deals in a span of three business days. Cravath is representing:
Accolades
August 10, 2023
On August 9, 2023, Cravath partner David J. Perkins was named a 2023 “Dealmaker of the Year” by the New York Law Journal. The award recognizes “talented and hardworking transactional lawyers who can close deals that make headlines.” Winners will be featured online and honored at an event in October.
Activities & Publications
June 22, 2023
On June 19, 2023, Cravath partner Arvind Ravichandran was featured as part of Law360’s 2023 “Rising Stars” series as one of the top tax attorneys in the nation under the age of 40. The related profile highlights Arvind’s representation of Occidental Petroleum Corp. in its $57 billion acquisition of Anadarko Petroleum Corp. and Novartis in its $29.8 billion spin‑off of the eye care devices business Alcon.
Activities & Publications
May 15, 2023
Cravath partners Alyssa K. Caples and Kelly M. Smercina participated in the International Bar Association’s 38th International Financial Law Conference, which was held from May 10‑12, 2023 in Lisbon, Portugal. Alyssa co‑chaired a panel entitled “Cutting the Apron Strings: the Start‑up’s Journey from VC Financing to IPO,” which reviewed key exit strategy considerations for start‑ups and venture capital funds and the benefits and disadvantages of the IPO route, including enhanced liquidity for investors, access to capital, maintenance of control and employee equity incentives, but also exposure to market volatility and regulatory burdens. Kelly spoke on a panel entitled “Here, There or Everywhere: Taking the Decision on Where to List and Why?,” which examined the current listing landscape and the competitive position of stock exchanges globally, including the current trends and future outlook of the IPO and listing market.
Activities & Publications
May 12, 2023
Cravath partner Richard Hall served as contributing editor of The Legal 500’s 2023 “Mergers & Acquisitions Country Comparative Guide,” which was published in May 2023. The guide provides a pragmatic overview of M&A laws and regulations across a variety of jurisdictions. Richard authored the United States chapter of the guide, which reviews M&A trends, the current state of the market and key considerations for companies and shareholders.
Deals & Cases
September 19, 2023
On September 19, 2023, affiliates of private investment firm Lindsay Goldberg, in partnership with the company’s management, announced the completion of an investment in The Kleinfelder Group, a leading engineering, design, construction management, construction materials inspection and testing, and environmental professional services firm. Cravath is representing Lindsay Goldberg in connection with the transaction.
Deals & Cases
September 18, 2023
On September 18, 2023, OMERS Private Equity announced the signing of a definitive agreement to acquire a majority stake in Knight Commercial, a leading provider of commercial restoration services. Cravath is representing OMERS Private Equity in connection with the transaction.
Deals & Cases
September 13, 2023
On September 12, 2023, J.D. Power, a global leader in data analytics, announced a definitive agreement to acquire Autovista Group, a leading pan‑European and Australian automotive data, analytics and industry insights provider. Cravath is representing European alternative asset management firm Hayfin Capital Management, which currently owns Autovista Group, as U.S. counsel in connection with the transaction.
Deals & Cases
August 30, 2023
Cravath represented the lead arrangers in connection with senior facilities to finance the pending acquisition of Palex Medical by funds advised by the private equity firms Apax Partners LLP and Fremman Capital. Palex Medical is a leading provider of high value‑added medical technology equipment and solutions in Southern Europe.
Deals & Cases
August 15, 2023
On August 14, 2023, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, managed by DRI Capital Inc., announced that it has purchased a second royalty interest in the worldwide net sales of ORSERDU®, the first approved targeted therapy used in the treatment of postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression despite prior endocrine therapy. DRI Healthcare entered into a purchase agreement with Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. for an upfront purchase price of $130 million. In addition to running royalties, DRI Healthcare is also entitled to receive milestone payments of up to $40 million on the achievement of sales performance thresholds. Cravath represented DRI Capital Inc. in connection with the transaction.
Firm News
August 14, 2023
Between July 28 and August 11, 2023, Cravath advised on nine announced deals, including seven deals in a span of three business days. Cravath is representing:
Accolades
August 10, 2023
On August 9, 2023, Cravath partner David J. Perkins was named a 2023 “Dealmaker of the Year” by the New York Law Journal. The award recognizes “talented and hardworking transactional lawyers who can close deals that make headlines.” Winners will be featured online and honored at an event in October.
Activities & Publications
June 22, 2023
On June 19, 2023, Cravath partner Arvind Ravichandran was featured as part of Law360’s 2023 “Rising Stars” series as one of the top tax attorneys in the nation under the age of 40. The related profile highlights Arvind’s representation of Occidental Petroleum Corp. in its $57 billion acquisition of Anadarko Petroleum Corp. and Novartis in its $29.8 billion spin‑off of the eye care devices business Alcon.
Activities & Publications
May 15, 2023
Cravath partners Alyssa K. Caples and Kelly M. Smercina participated in the International Bar Association’s 38th International Financial Law Conference, which was held from May 10‑12, 2023 in Lisbon, Portugal. Alyssa co‑chaired a panel entitled “Cutting the Apron Strings: the Start‑up’s Journey from VC Financing to IPO,” which reviewed key exit strategy considerations for start‑ups and venture capital funds and the benefits and disadvantages of the IPO route, including enhanced liquidity for investors, access to capital, maintenance of control and employee equity incentives, but also exposure to market volatility and regulatory burdens. Kelly spoke on a panel entitled “Here, There or Everywhere: Taking the Decision on Where to List and Why?,” which examined the current listing landscape and the competitive position of stock exchanges globally, including the current trends and future outlook of the IPO and listing market.
Activities & Publications
May 12, 2023
Cravath partner Richard Hall served as contributing editor of The Legal 500’s 2023 “Mergers & Acquisitions Country Comparative Guide,” which was published in May 2023. The guide provides a pragmatic overview of M&A laws and regulations across a variety of jurisdictions. Richard authored the United States chapter of the guide, which reviews M&A trends, the current state of the market and key considerations for companies and shareholders.
Key Contacts
Explore
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. © 2023 Cravath, Swaine & Moore LLP.